4 completed, 1 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow AS03 adjuvant: new trials by email Literature Review of AS03 adjuvant trials Research Report on AS03 adjuvant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Immunogenicity Study of MT-2766 in Japanese Adults(COVID-19) MT-2766 High dose (3.75 µg), Placebo, MT-2766 Low dose - SARS-CoV-2 Infection | Phase 1 / Phase 2 | Terminated | Medicago | 128 | 2021-10-02 | 2023-11-07 |
| A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3 - Influenza, Human | Phase 2 | Completed | GlaxoSmithKline | 833 | 2021-03-16 | 2023-10-10 |
| Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 VN, IN, dk/BANG - Influenza A Virus, H5N1 Subtype | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 720 | 2018-03-15 | 2020-07-14 |
| Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant - Influenza A Virus, H5N1 Subtype | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2013-07-01 | 2019-02-12 |
| Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant - Influenza | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 43 | 2012-03-20 | 2019-02-26 |
Influenza in Birds (2) · Influenza, Human (2) · COVID-19 (1) · Virus Diseases (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Biomedical Advanced Research and Development Authority (1) · GlaxoSmithKline (1) · Medicago (1)
United States (4) · Japan (1)
John S Tsang, Ph.D. (1) · Nadine Rouphael, MD (1)
PMID 30302282, PMID 34174187, PMID 39702896
U19AI090023 (1)